The Life Sciences team advised BridgeBio Pharma as it launched a new subsidiary, QED Therapeutics, to drive the development of infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, which has been implicated as a driver mutation across multiple forms of cancer. Infigratinib is licensed to QED from Novartis, and BridgeBio has made an initial financial commitment of $65 million, inclusive of an upfront payment to Novartis as well as an equity investment in QED.
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
The Goodwin team was led by partner Maggie Wong and associate Noelle Dubiansky and included partner Theresa Kavanaugh; and associates Emily Beman,
For additional details on the transactions, please read the press release.
BridgeBio is a clinical-stage biotech company developing novel, genetically targeted therapies to improve the lives of patients. The BridgeBio approach combines a traditional focus on drug development with a unique corporate model, allowing rapid translation of early stage science into medicines that treat disease at its source.
The Goodwin team was led by partner Maggie Wong and associate Noelle Dubiansky and included partner Theresa Kavanaugh; and associates Emily Beman,
For additional details on the transactions, please read the press release.